Equity Overview
Price & Market Data
Price: $1.25
Daily Change: +$0.049 / 3.92%
Range: $1.20 - $1.29
Market Cap: $23,551,892
Volume: 119,077
Performance Metrics
1 Week: 6.03%
1 Month: 7.89%
3 Months: -41.98%
6 Months: -24.54%
1 Year: 86.39%
YTD: -32.04%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.